Skip to main content
main-content
Erschienen in: Current Allergy and Asthma Reports 9/2022

20.05.2022 | Asthma (V Ortega, Section Editor)

Alpha-1 Asthma Overlap Syndrome: a Clinical Overview

verfasst von: Manuel Izquierdo, Himanshu Rawal, Michael Armstrong, Chad R. Marion

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Alpha-1 antitrypsin deficiency (AATD) is one of the most common genetic diseases that is associated with severe complications and yet remains underdiagnosed. The pulmonary symptoms of both AATD and asthma include cough, excessive sputum production, dyspnea, and wheezing. These symptoms overlap significantly leading to difficulty distinguishing between these two conditions and suspicion that there may be an overlap syndrome. We aim to discuss the pathophysiology, clinical manifestations, and treatment of both alpha-1 antitrypsin and asthma and how they may overlap.

Recent Findings

Recent literature suggests that there is an association between asthma and AATD. This association has been hypothesized to be secondary to an imbalance of elastase and anti-elastase leading to a pro-inflammatory state in patients with AATD.

Summary

This review serves to overview the pathophysiology, clinical manifestations, and treatment of alpha-1 antitrypsin, asthma, and the increasingly recognized intersection of the two, AATD-asthma overlap syndrome.
Literatur
1.
Zurück zum Zitat de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382–97. PubMedCrossRef de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382–97. PubMedCrossRef
2.
Zurück zum Zitat Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382:1443–55. PubMedCrossRef Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382:1443–55. PubMedCrossRef
4.
Zurück zum Zitat Willis-Owen SAG, Cookson WOC, Moffatt MF. The genetics and genomics of asthma. Annu Rev Genomics Hum Genet. 2018;19:223–46. PubMedCrossRef Willis-Owen SAG, Cookson WOC, Moffatt MF. The genetics and genomics of asthma. Annu Rev Genomics Hum Genet. 2018;19:223–46. PubMedCrossRef
5.
Zurück zum Zitat Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–6. PubMedCrossRef Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–6. PubMedCrossRef
7.
Zurück zum Zitat McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and management of asthma in adults: a review. 2017;318:279–90. McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and management of asthma in adults: a review. 2017;318:279–90.
8.
Zurück zum Zitat Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78. PubMedCrossRef Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78. PubMedCrossRef
9.
Zurück zum Zitat Ortega VE, Li X, O’Neal WK, Lackey L, Ampleford E, Hawkins GA, et al. The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. Am J Respir Crit Care Med. 2020;201:540–54. PubMedPubMedCentralCrossRef Ortega VE, Li X, O’Neal WK, Lackey L, Ampleford E, Hawkins GA, et al. The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. Am J Respir Crit Care Med. 2020;201:540–54. PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Cummings EE, O’Reilly LP, King DE, Silverman RM, Miedel MT, Luke CJ, et al. Deficient and null variants of SERPINA1 are proteotoxic in a Caenorhabditis elegans model of alpha1-antitrypsin deficiency. PLoS ONE. 2015;10:e0141542. PubMedPubMedCentralCrossRef Cummings EE, O’Reilly LP, King DE, Silverman RM, Miedel MT, Luke CJ, et al. Deficient and null variants of SERPINA1 are proteotoxic in a Caenorhabditis elegans model of alpha1-antitrypsin deficiency. PLoS ONE. 2015;10:e0141542. PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360:2749–57. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360:2749–57.
13.
Zurück zum Zitat Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88:891–7. Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88:891–7.
14.
Zurück zum Zitat King GG, James A, Harkness L, Wark PAB. Pathophysiology of severe asthma: we’ve only just started. Respirology. 2018;23:262–71. PubMedCrossRef King GG, James A, Harkness L, Wark PAB. Pathophysiology of severe asthma: we’ve only just started. Respirology. 2018;23:262–71. PubMedCrossRef
15.
Zurück zum Zitat Lemanske RF Jr. Inflammatory events in asthma: an expanding equation. J Allergy Clin Immunol. 2000;105:S633–6. PubMedCrossRef Lemanske RF Jr. Inflammatory events in asthma: an expanding equation. J Allergy Clin Immunol. 2000;105:S633–6. PubMedCrossRef
16.
Zurück zum Zitat Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–8. PubMedCrossRef Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–8. PubMedCrossRef
17.
Zurück zum Zitat Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75:311–25. PubMedCrossRef Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75:311–25. PubMedCrossRef
18.
Zurück zum Zitat Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138:327–36. PubMedCrossRef Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138:327–36. PubMedCrossRef
19.
Zurück zum Zitat Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59:441–5. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59:441–5.
20.
Zurück zum Zitat Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215–21. PubMedCrossRef Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215–21. PubMedCrossRef
21.
Zurück zum Zitat Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with alpha-1-antitrypsin deficiency. Clin Radiol. 1992;45:260–6. PubMedCrossRef Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with alpha-1-antitrypsin deficiency. Clin Radiol. 1992;45:260–6. PubMedCrossRef
22.
Zurück zum Zitat Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277–84. PubMedCrossRef Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277–84. PubMedCrossRef
23.
Zurück zum Zitat Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Bénichou J, et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415–9. PubMedCrossRef Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Bénichou J, et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415–9. PubMedCrossRef
25.
Zurück zum Zitat Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004;22:789–815. PubMedCrossRef Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004;22:789–815. PubMedCrossRef
26.
Zurück zum Zitat Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol. 2010;125:830–7. PubMedCrossRef Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol. 2010;125:830–7. PubMedCrossRef
27.
Zurück zum Zitat Shah A, Panjabi C. Allergic aspergillosis of the respiratory tract. Eur Respir Rev. 2014;23:8–29. PubMedCrossRef Shah A, Panjabi C. Allergic aspergillosis of the respiratory tract. Eur Respir Rev. 2014;23:8–29. PubMedCrossRef
28.
Zurück zum Zitat Eden E, Strange C, Holladay B, Xie L. Asthma and allergy in alpha-1 antitrypsin deficiency. Respir Med. 2006;100:1384–91. PubMedCrossRef Eden E, Strange C, Holladay B, Xie L. Asthma and allergy in alpha-1 antitrypsin deficiency. Respir Med. 2006;100:1384–91. PubMedCrossRef
29.
Zurück zum Zitat Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol. 2013;111:458–64. PubMedCrossRef Siri D, Farah H, Hogarth DK. Distinguishing alpha1-antitrypsin deficiency from asthma. Ann Allergy Asthma Immunol. 2013;111:458–64. PubMedCrossRef
30.
Zurück zum Zitat Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am J Respir Crit Care Med. 1997;156:68–74. PubMedCrossRef Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am J Respir Crit Care Med. 1997;156:68–74. PubMedCrossRef
31.
Zurück zum Zitat Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003;123:765–71. PubMedCrossRef Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003;123:765–71. PubMedCrossRef
32.
Zurück zum Zitat Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61:461–7. PubMedCrossRef Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61:461–7. PubMedCrossRef
33.
Zurück zum Zitat Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128:1989–94. PubMedCrossRef Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128:1989–94. PubMedCrossRef
34.
Zurück zum Zitat Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1in patients with severe hereditaryα1-antitrypsin deficiency? Eur Respir J. 1997;10:2260–3. PubMedCrossRef Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1in patients with severe hereditaryα1-antitrypsin deficiency? Eur Respir J. 1997;10:2260–3. PubMedCrossRef
35.
Zurück zum Zitat Wencker M, Fuhrmann B, Konietzko N, Banik N. Longitudinal follow-up of patients with α1-protease inhibitor deficiency before and during therapy with IV α1-protease inhibitor. Chest. 2001;119:737–44. PubMedCrossRef Wencker M, Fuhrmann B, Konietzko N, Banik N. Longitudinal follow-up of patients with α1-protease inhibitor deficiency before and during therapy with IV α1-protease inhibitor. Chest. 2001;119:737–44. PubMedCrossRef
36.
Zurück zum Zitat Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443–52. PubMedPubMedCentralCrossRef Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443–52. PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Society AT, Society ER. ATS/ERS statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. 2003;168. Society AT, Society ER. ATS/ERS statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. 2003;168.
38.
Zurück zum Zitat Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency. Pi Z Acta Med Scand. 1978;204:345–51. CrossRef Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency. Pi Z Acta Med Scand. 1978;204:345–51. CrossRef
39.
Zurück zum Zitat Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Chest. 1983;77:14–27. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Chest. 1983;77:14–27.
40.
Zurück zum Zitat McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111:394–403. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111:394–403.
41.
Zurück zum Zitat Aiello M, Frizzelli A, Pisi R, Fantin A, Ghirardini M, Marchi L, et al. Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. J Asthma. 2020;1–8. Aiello M, Frizzelli A, Pisi R, Fantin A, Ghirardini M, Marchi L, et al. Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. J Asthma. 2020;1–8.
42.
Zurück zum Zitat Colp C, Pappas J, Moran D, Lieberman J. Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest. 1993;103:812–5. PubMedCrossRef Colp C, Pappas J, Moran D, Lieberman J. Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest. 1993;103:812–5. PubMedCrossRef
43.
Zurück zum Zitat van Veen IH, ten Brinke A, van der Linden AC, Rabe KF, Bel EH. Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. Respir Med. 2006;100:1534–9. PubMedCrossRef van Veen IH, ten Brinke A, van der Linden AC, Rabe KF, Bel EH. Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. Respir Med. 2006;100:1534–9. PubMedCrossRef
44.
Zurück zum Zitat Montealegre F, Delgado A, Toro A, Vargas W, Chardon D, Bayona M, et al. Alfa 1 antitrypsin and protease levels in Puerto Rican asthmatics: a pilot study. P R Health Sci J. 2006;25:117–25. PubMed Montealegre F, Delgado A, Toro A, Vargas W, Chardon D, Bayona M, et al. Alfa 1 antitrypsin and protease levels in Puerto Rican asthmatics: a pilot study. P R Health Sci J. 2006;25:117–25. PubMed
45.
Zurück zum Zitat Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma–results from the ALA-ACRC low-dose theophylline trial. J Asthma. 2007;44:605–8. PubMedCrossRef Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma–results from the ALA-ACRC low-dose theophylline trial. J Asthma. 2007;44:605–8. PubMedCrossRef
46.
Zurück zum Zitat Miravitlles M, Vila S, Torrella M, Balcells E, Rodriguez-Frias F, de la Roza C, et al. Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir Med. 2002;96:186–92. PubMedCrossRef Miravitlles M, Vila S, Torrella M, Balcells E, Rodriguez-Frias F, de la Roza C, et al. Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir Med. 2002;96:186–92. PubMedCrossRef
47.
Zurück zum Zitat Suarez-Lorenzo I, de Castro FR, Cruz-Niesvaara D, Herrera-Ramos E, Rodriguez-Gallego C, Carrillo-Diaz T. Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites. Clin Transl Allergy. 2018;8:44. PubMedPubMedCentralCrossRef Suarez-Lorenzo I, de Castro FR, Cruz-Niesvaara D, Herrera-Ramos E, Rodriguez-Gallego C, Carrillo-Diaz T. Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites. Clin Transl Allergy. 2018;8:44. PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Vignola AM, Bonanno A, Mirabella A, Riccobono L, Mirabella F, Profita M, et al. Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med. 1998;157:505–11. PubMedCrossRef Vignola AM, Bonanno A, Mirabella A, Riccobono L, Mirabella F, Profita M, et al. Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med. 1998;157:505–11. PubMedCrossRef
49.
Zurück zum Zitat Gharib SA, Nguyen EV, Lai Y, Plampin JD, Goodlett DR, Hallstrand TS. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol. 2011;128(1176–1184):e6. Gharib SA, Nguyen EV, Lai Y, Plampin JD, Goodlett DR, Hallstrand TS. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol. 2011;128(1176–1184):e6.
50.
Zurück zum Zitat Cohen AB, Rossi M. Neutrophils in normal lungs. Am Rev Respir Dis. 1983;127:S3-9. PubMed Cohen AB, Rossi M. Neutrophils in normal lungs. Am Rev Respir Dis. 1983;127:S3-9. PubMed
51.
Zurück zum Zitat Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992;89:1478–84. PubMedPubMedCentralCrossRef Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992;89:1478–84. PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, et al. Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120:4236–50. PubMedPubMedCentralCrossRef Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, et al. Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120:4236–50. PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Amitani R, Kuze F. [Mucoid Pseudomonas aeruginosa infection in cystic fibrosis]. Nihon Rinsho. 1991;49:2312–6. PubMed Amitani R, Kuze F. [Mucoid Pseudomonas aeruginosa infection in cystic fibrosis]. Nihon Rinsho. 1991;49:2312–6. PubMed
54.
Zurück zum Zitat Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis. 1985;132:417–33. Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis. 1985;132:417–33.
55.
Zurück zum Zitat Chetty A, Davis P, Infeld M. Effect of elastase on the directional migration of lung fibroblasts within a three-dimensional collagen matrix. Exp Lung Res. 1995;21:889–99. PubMedCrossRef Chetty A, Davis P, Infeld M. Effect of elastase on the directional migration of lung fibroblasts within a three-dimensional collagen matrix. Exp Lung Res. 1995;21:889–99. PubMedCrossRef
56.
Zurück zum Zitat Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H, Inoue H. Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am J Respir Crit Care Med. 1996;153:1405–11. PubMedCrossRef Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H, Inoue H. Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am J Respir Crit Care Med. 1996;153:1405–11. PubMedCrossRef
58.
Zurück zum Zitat O’Dwyer CA, O’Brien ME, Wormald MR, White MM, Banville N, Hurley K, et al. The BLT1 inhibitory function of alpha-1 antitrypsin augmentation therapy disrupts leukotriene B4 neutrophil signaling. J Immunol. 2015;195:3628–41. PubMedCrossRef O’Dwyer CA, O’Brien ME, Wormald MR, White MM, Banville N, Hurley K, et al. The BLT1 inhibitory function of alpha-1 antitrypsin augmentation therapy disrupts leukotriene B4 neutrophil signaling. J Immunol. 2015;195:3628–41. PubMedCrossRef
59.
Zurück zum Zitat Nita IM, Serapinas D, Janciauskiene SM. Alpha1-antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol. 2007;39:1165–76. PubMedCrossRef Nita IM, Serapinas D, Janciauskiene SM. Alpha1-antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol. 2007;39:1165–76. PubMedCrossRef
60.
Zurück zum Zitat Baraldo S, Turato G, Lunardi F, Bazzan E, Schiavon M, Ferrarotti I, et al. Immune activation in alpha1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm. Am J Respir Crit Care Med. 2015;191:402–9. Baraldo S, Turato G, Lunardi F, Bazzan E, Schiavon M, Ferrarotti I, et al. Immune activation in alpha1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm. Am J Respir Crit Care Med. 2015;191:402–9.
61.
Zurück zum Zitat Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, et al. alpha1-Antitrypsin deficiency. Nat Rev Primer. 2016;2:16051. CrossRef Greene CM, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, et al. alpha1-Antitrypsin deficiency. Nat Rev Primer. 2016;2:16051. CrossRef
62.
Zurück zum Zitat Bazzan E, Tine M, Biondini D, Benetti R, Baraldo S, Turato G, et al. alpha1-Antitrypsin polymerizes in alveolar macrophages of smokers with and without alpha1-antitrypsin deficiency. Chest. 2018;154:607–16. PubMedCrossRef Bazzan E, Tine M, Biondini D, Benetti R, Baraldo S, Turato G, et al. alpha1-Antitrypsin polymerizes in alveolar macrophages of smokers with and without alpha1-antitrypsin deficiency. Chest. 2018;154:607–16. PubMedCrossRef
63.
Zurück zum Zitat Kueppers F, Sanders C. State-of-the-are testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38:108–14. PubMedCrossRef Kueppers F, Sanders C. State-of-the-are testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38:108–14. PubMedCrossRef
64.
Zurück zum Zitat Luisetti M. Diagnosis and management of alpha1-antitrypsin deficiency. Breathe. 2007;4:38–46. Luisetti M. Diagnosis and management of alpha1-antitrypsin deficiency. Breathe. 2007;4:38–46.
65.
Zurück zum Zitat World Health Organization. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397–415. World Health Organization. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397–415.
66.
Zurück zum Zitat Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison D, Ulrik CS, et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468–72. PubMedCrossRef Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison D, Ulrik CS, et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468–72. PubMedCrossRef
67.
Zurück zum Zitat Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33:1345–53. PubMedCrossRef Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33:1345–53. PubMedCrossRef
68.
Zurück zum Zitat Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severeα1antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–8. PubMedCrossRef Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severeα1antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–8. PubMedCrossRef
69.
Zurück zum Zitat Dauriat G, Mal H, Jebrak G, Brugière O, Castier Y, Camuset J, et al. Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis. 2006;1:201–6. PubMedPubMedCentral Dauriat G, Mal H, Jebrak G, Brugière O, Castier Y, Camuset J, et al. Functional results of unilateral lung volume reduction surgery in alpha1-antitrypsin deficient patients. Int J Chron Obstruct Pulmon Dis. 2006;1:201–6. PubMedPubMedCentral
70.
Zurück zum Zitat Cassina PC, Teschler H, Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in α1-antitrypsin deficiency versus smoker’s emphysema. Eur Respir J. 1998;12:1028–32. PubMedCrossRef Cassina PC, Teschler H, Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in α1-antitrypsin deficiency versus smoker’s emphysema. Eur Respir J. 1998;12:1028–32. PubMedCrossRef
Metadaten
Titel
Alpha-1 Asthma Overlap Syndrome: a Clinical Overview
verfasst von
Manuel Izquierdo
Himanshu Rawal
Michael Armstrong
Chad R. Marion
Publikationsdatum
20.05.2022
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 9/2022
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-022-01036-z

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.